Literature DB >> 12849712

Chronic diffuse musculoskeletal pain, fibromyalgia and co-morbid unexplained clinical conditions.

Leslie A Aaron1, Dedra Buchwald.   

Abstract

This chapter reviews our current knowledge on the presence of overlapping syndromes in one form of chronic diffuse pain, fibromyalgia. Patients with fibromyalgia often present with signs and symptoms of other unexplained clinical conditions, including chronic fatigue syndrome, irritable bowel syndrome, temporomandibular disorders, and multiple chemical sensitivities. The high prevalence, impact on function and opportunities for treatment underscore the need for clinicians and researchers to screen routinely for co-morbid unexplained clinical conditions among persons with fibromyalgia. We, therefore, describe a simple approach to screening for such conditions in accordance with published criteria. Interventions should directly address both fibromyalgia symptoms and co-morbid unexplained clinical conditions, as well as the multiple factors that propagate pain, fatigue and limitations in function.

Entities:  

Mesh:

Year:  2003        PMID: 12849712     DOI: 10.1016/s1521-6942(03)00033-0

Source DB:  PubMed          Journal:  Best Pract Res Clin Rheumatol        ISSN: 1521-6942            Impact factor:   4.098


  37 in total

1.  Sustained pain reduction through affective self-awareness in fibromyalgia: a randomized controlled trial.

Authors:  Michael C Hsu; Howard Schubiner; Mark A Lumley; John S Stracks; Daniel J Clauw; David A Williams
Journal:  J Gen Intern Med       Date:  2010-06-08       Impact factor: 5.128

2.  Clinical findings and pain symptoms as potential risk factors for chronic TMD: descriptive data and empirically identified domains from the OPPERA case-control study.

Authors:  Richard Ohrbach; Roger B Fillingim; Flora Mulkey; Yoly Gonzalez; Sharon Gordon; Henry Gremillion; Pei-Feng Lim; Margarete Ribeiro-Dasilva; Joel D Greenspan; Charles Knott; William Maixner; Gary Slade
Journal:  J Pain       Date:  2011-11       Impact factor: 5.820

3.  The development and psychometric validation of the central sensitization inventory.

Authors:  Tom G Mayer; Randy Neblett; Howard Cohen; Krista J Howard; Yun H Choi; Mark J Williams; Yoheli Perez; Robert J Gatchel
Journal:  Pain Pract       Date:  2011-09-27       Impact factor: 3.183

Review 4.  Fibromyalgia: a rheumatologic diagnosis?

Authors:  Gerhard K M Endresen
Journal:  Rheumatol Int       Date:  2007-07-20       Impact factor: 2.631

5.  [Definition, classification and diagnosis of fibromyalgia syndrome].

Authors:  W Eich; W Häuser; E Friedel; A Klement; M Herrmann; F Petzke; M Offenbächer; M Schiltenwolf; C Sommer; T Tölle; P Henningsen
Journal:  Schmerz       Date:  2008-06       Impact factor: 1.107

6.  Further validation of a model of fibromyalgia syndrome in the rat.

Authors:  Paul G Green; Pedro Alvarez; Robert W Gear; Dennis Mendoza; Jon D Levine
Journal:  J Pain       Date:  2011-04-09       Impact factor: 5.820

7.  Relationship between temporomandibular disorders, widespread palpation tenderness, and multiple pain conditions: a case-control study.

Authors:  Hong Chen; Gary Slade; Pei Feng Lim; Vanessa Miller; William Maixner; Luda Diatchenko
Journal:  J Pain       Date:  2012-10       Impact factor: 5.820

Review 8.  Pathophysiology of fibromyalgia.

Authors:  Laurence A Bradley
Journal:  Am J Med       Date:  2009-12       Impact factor: 4.965

9.  Role and rationale for the use of milnacipran in the management of fibromyalgia.

Authors:  Jay D Kranzler; R Michael Gendreau
Journal:  Neuropsychiatr Dis Treat       Date:  2010-05-25       Impact factor: 2.570

10.  Effects of naltrexone on pain sensitivity and mood in fibromyalgia: no evidence for endogenous opioid pathophysiology.

Authors:  Jarred W Younger; Alex J Zautra; Eric T Cummins
Journal:  PLoS One       Date:  2009-04-13       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.